SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ruffian who wrote (27)12/27/2006 7:48:30 AM
From: Keith Feral of 418
 
Should see some more follow through today. The company announced their phase 2 for breast cancer. Cofactor's replacement of leucovorin for folate treatment in oncology is used in almost every type of first line therapy - colorectal cancer, breast cancer are the 2 biggest markets. The cofactor results are better than most of the results from combination therapy. It will soon be time to start rehashing the phase 2 results with the European trials finishing in the next month or two. Results should be on the way by June for the phase 2 b in Europe. Also, by that time, we could see the interim phase 3 results with cofactor and avastin for the first 400 patients. There will be another interim study after 800 patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News